CEG has submitted a planning application seeking to revitalise Drapers Yard on Marshall Street in Leeds for Labcorp – a global diagnostics and drug development company at the heart of life-science innovation in Leeds.
It marks further investment by Labcorp Drug Development into the local economy. The company currently operates out of two sites in Leeds and plans to consolidate the team into one building for more efficient, collaborative working, as well as having the opportunity to double in size, retaining and creating almost 300 highly skilled scientific and healthcare jobs in the city.
Labcorp delivers vital medical research and has worked on most of the available COVID-19 vaccines and is currently involved in more than 400 studies for COVID-19 globally.
The new facility offers an exciting opportunity to offer enhanced scientific outcomes and clinical trial testing, something which has become all the more vital during the current pandemic.
“The new Covance by Labcorp facility will be a gold standard clinical pharmacology investigational unit, commensurate with the outstanding global reputation of the UK Life Sciences sector,” said Oren Cohen, chief medical officer and general manager, Clinical Pharmacology Services at Covance by Labcorp.
“The new facility will allow us to continue our important work to test next-generation medicines that may improve health and improve lives in an exciting new environment that highlights the growing role of Leeds as a leader in life sciences.”
CEG would manage the delivery of the new facility and aims to enable occupation by summer 2022. It would include a 100-bed clinic, pharmacy and Labcorp’s UK office headquarters.
Antonia Martin-Wright, head of investment at CEG, said: “This is a really exciting opportunity to deliver a UK Centre of Excellence for Labcorp. It will be a sustainable and energy efficient development, designed with occupant well-being in mind.
“It will bring a welcome economic boost to Temple supporting the city’s post-covid recovery plans and helping to create a cluster for science, knowledge and innovation.
“The commitment to the site will also help to build further confidence that this is a fantastic business destination, just minutes from Leeds City Station, helping to attract future inward investment opportunities.”
Councillor James Lewis, leader of Leeds City Council, said: “This is a hugely-exciting piece of news for Leeds, and one that will strengthen the city’s reputation as a place where cutting-edge tech and a sense of history come together to positive effect.
“We already have an unrivalled health ecosystem, with four out of five NHS national offices being based here. In addition, Leeds is home to one of the largest concentrations of medical device companies in the UK and a rich pool of health, science and digital talent.
“Labcorp’s medical research, drug development and clinical trial testing can change lives and Leeds’s supporting role in this work is a real source of pride. The commitment to retaining and creating high-quality jobs in the city is also a timely boost as we begin our recovery from the COVID-19 pandemic.”